{"entity":{"id":"xuanzhu-biopharmaceutical","kind":"company","name":"Xuanzhu Biopharmaceutical","aka":["Xuanzhu Biopharmaceutical Co., Ltd."],"tldr":"Xuanzhu Biopharmaceutical is a China-based biotechnology company running 3 late-stage cancer trials of XZP-3287 and XZP-5955 in HR-positive / HER2-negative breast cancer and non-small-cell lung cancer.","summary":"Xuanzhu Biopharmaceutical, based in Beijing, China, is a biotechnology company. Xuanzhu Biopharmaceutical is a China-based biopharmaceutical company developing drugs for digestive system diseases, oncology and NASH (non-alcoholic fatty liver disease). On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing XZP-3287 and XZP-5955 in HR-positive / HER2-negative breast cancer and non-small-cell lung cancer. The largest, NCT05257395 (A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer), plans to enrol 397 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.xuanzhubio.com"},{"label":"ClinicalTrials.gov: trials led by Xuanzhu Biopharmaceutical","url":"https://clinicaltrials.gov/search?lead=Xuanzhu%20Biopharmaceutical%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["breast-hr-positive","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["xzp-3287"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05257395","nct04996121"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Beijing","country":"CN","companyType":"biotech","website":"https://www.xuanzhubio.com","founded":2008,"investors":[],"funding":[]},"route":"/companies/xuanzhu-biopharmaceutical/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"xzp-3287","kind":"drug","name":"XZP-3287","route":"/drugs/xzp-3287/"}],"trial":[{"id":"nct05077449","kind":"trial","name":"A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer","route":"/trials/nct05077449/"},{"id":"nct05257395","kind":"trial","name":"A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer","route":"/trials/nct05257395/"},{"id":"nct04996121","kind":"trial","name":"A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct04996121/"}]}}